Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-03 · accession 0001213900-22-000761 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-05 | 2022-01-03 | RLMD | Kelly Paul Edward | Dir | M - OptEx | $3.24 | -20.0K | 187.3K | -10% | -$64.8K |
| D | 2022-01-05 | 2022-01-03 | RLMD | Kelly Paul Edward | Dir | M - OptEx | $0.00 | -20.0K | 30.5K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-03 | M | D | 20,000 | $3.24 | 187,295 | D | — | — | |
| 2 | Derivative | Options to purchase common stock | 2022-01-03 | M | D | 20,000 | $0.00 | 30,500 | D | $3.24 · 2017-10-20 to 2027-10-20 | 20,000 Common Stock | (F2) Not applicable. (F1) The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. |